ClinicalTrials.gg
CompletedNCT03923387PANDAUpdated Jul 29, 2026Results posted

Study to Evaluate the Safety and Effectiveness of MynxGrip Vascular Closure Device

An interventional study of MynxGrip and Manual compression in Endovascular, sponsored by Cordis US Corp.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Cordis US Corp. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the safety and effectiveness of MynxGrip, in hemostasis of common femoral artery puncture site, compared with manual compression hemostasis in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.

Read the detailed description

Effectiveness: to superiority to the control group in time to hemostasis. Comparison of time to ambulation, procedure success rate, length of stay in hospital, device success rate.

Safety-Major/Minor complication rate, adverse events, SAEs as compared to control.

02

Conditions studied

  • Endovascular

Keywords

  • Vascular closure
03

In context

Lead sponsor

Cordis US Corp. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 18 years of age;
  2. Patients who are able and willing to sign the form;
  3. Patients who agree to follow all study visits and procedures;
  4. Patients who plan to receive the diagnostic or interventional endovascular procedures via percutaneous common femoral artery puncture;
  5. Patients who are able to walk, as judged by the investigators.

Exclusion criteria

Exclusion Criteria:

  1. Patients are proved to have peripheral vascular disease according to any of the following situations:

    1. Patients showing severe claudication after walking less than 200 meters,
    2. No palpable pulse on the patients' affected limbs,
    3. Patients having received surgical procedures involving the ipsilateral common femoral artery
    4. Patients having received percutaneous transluminal angioplasty (PTA), stent placement, or vascular graft in the ipsilateral common femoral artery;
  2. Patients with morbid obesity ( > 40 kg/m2);
  3. Patients with a myocardial infarction (MI) with acute elevated ST segment ≤24 hours prior to procedure;
  4. Patients with the prior procedure in the ipsilateral common femoral artery ≤30 days;
  5. Patients having received ipsilateral vascular closure device;
  6. Patients with bleeding disorders such as thrombocytopenia ( count \< 100,000/ mm3), hemophilia, von Willebrand disease or severe anemia ( \< 10 g/dL, Hct \< 30%);
  7. Patients with documented > 1.5 or patients currently receiving glycoprotein IIb/IIIa platelet inhibitors;
  8. Patients with symptoms of local infection or inflammation in the groin;
  9. Patients who are participating in any other clinical studies on drugs or medical devices at the same time;
  10. Patients who are pregnant or in lactation;
  11. Patients with known allergy to contrast medium;
  12. Patients with known allergy to polyethylene glycol;
  13. Patients with treated but still uncontrolled hypertension (systolic pressure>180 mmHg or diastolic pressure>110 mmHg);
  14. Patients with known diseases;
  15. Patients who are receiving long-term therapy;
  16. Patients with expected life of less than 30 days;
  17. Patients with unilateral or bilateral lower-extremity amputation;
  18. Patients who can't walk 6 meters (20 steps) without a support for any reason;
  19. Patients requiring prolonged length of stay [For example, the patient will receive the coronary artery bypass grafting (CABG) or the patient plans to receive the CABG ≤30 days after the surgery];
  20. Patients with mental disorders and cognitive impairment;
  21. Patients have participated into this study before; Intra-operative exclusion criteria;
  22. Patients with treated but still uncontrolled hypertension (systolic pressure>180 mmHg or diastolic pressure>110 mmHg);
  23. Patients implanted with a balloon pump inside the aorta;
  24. Patients whose common femoral artery is too thin (\<5 mm in diameter);
  25. Patients with obviously fibrotic, calcified, or >50% stenotic femoral artery;
  26. Patients having received puncture at other artery than the common femoral artery;
  27. Patients having received antegrade puncture;
  28. Patients having received arterial puncture at a number of different sites or who are suspected to have received posterior femoral arterial wall puncture;
  29. Patients implanted with ipsilateral venous sheath;
  30. Surgical findings or complications which the investigators consider may interfere with the patients' participation into the study (For example, the sheath deployment is difficult due to the scar, tortuous vessels, or use of the sheath with the other sizes than 5 Fr, 6 Fr or 7 Fr, or the sheath with the total length of >15.7 cm);
  31. Patients with preexisting hematoma, intraluminal thrombus, pseudoaneurysm, AV Fistula or any type of dissection;
  32. Patients requiring prolonged length of stay [For example, the patient will receive the coronary artery bypass grafting (CABG) or the patient plans to receive the CABG ≤30 days after the surgery];
  33. Patients who are included in another drug or medical device study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    MynxGrip

    MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.

    Device: MynxGrip

  • Active comparator
    Manual compression

    Manual compression hemostasis

    Other: Manual compression

Interventions

  • DeviceMynxGrip

    Vascular Closure

  • OtherManual compression

    Manual compression is a commonly used method to achieve hemostasis of femoral artery

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint: Time to Hemostasis

    The time to hemostasis is defined as the time from the sheath removal to the time to achieving hemostasis for the subject. The "hemostasis" here refers to that at the puncture site, there is no pulsating bleeding, nor expansionary/progressive hematoma.

    Time frame: Post procedure (time from the sheath removal to the time to achieving hemostasis)

  2. Primary Safety Endpoint: Major Complication Rate

    Defined as major complications during procedure, at discharge, and 30 days post procedure: vascular injury or vascular repair required; Permanent access site-related nerve injury; Access site-related nerve injury requiring a surgery; Access site-related bleeding requiring transfusion; New ipsilateral lower extremity ischemia discovered, which requires invasive/noninvasive intervention; Local access site-related infection combined with other indicators, which requires intervention; Classic signs/symptoms occurred in a short time after receiving the specified hemostasis procedures and generalized infection with positive blood culture, sepsis, which requiring intervention; Inflammatory reaction, including the local reaction and discharge of pus, which requires intervention

    Time frame: Through 30 days post procedure

Secondary outcomes

  1. Secondary Effectiveness Endpoint: Time to Ambulation

    Defined as the time (in minutes) from sheath removal to when the patient can walk about at least 6 meters (or 20 steps). Compare whether there are differences in the time to ambulation (for patients receiving a diagnostic procedure) between the two groups.

    Time frame: Post procedure

  2. Secondary Effectiveness Endpoint: Length of Hospital Stay

    Defined as the time (in minutes) from sheath removal to patient discharge (for patients receiving a diagnostic procedure). Compare whether there are differences in the length of stay (for patients receiving a diagnostic procedure) between the two groups.

    Time frame: Index procedure through discharge

  3. Secondary Effectiveness Endpoint: Procedure Success Rate

    Defined as successfully achieving hemostasis using the investigational medical device or control methods (including but are not limited to the assigned therapeutic method and other supplementary means) with absence of major complications. Compare whether there are differences in the procedure success rate (for patients receiving a diagnostic procedure) between the two groups.

    Time frame: Index procedure

  4. Secondary Effectiveness Endpoint: Device Success Rate

    Defined as the device being successfully removed in accordance with the standard operating procedure

    Time frame: Intraoperatively

  5. Secondary Safety Endpoint: Minor Complication Rate

    Compare whether there are differences in rates of minor complications between the two groups

    Time frame: Through 30 days post procedure

07

Results

Posted Jul 29, 2026

Participant flow

Study enrollment began with first patient on 24-Apr-2019 and ended with last patient on 21-Sep-2020.

Participant flow — Overall Study
MilestoneMynxGripManual Compression
Started204102
Completed18792
Not completed1710
Withdrew: Adverse event21
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up148
Withdrew: Physician decision10

Outcome measures

PrimaryPrimary Effectiveness Endpoint: Time to Hemostasis

The time to hemostasis is defined as the time from the sheath removal to the time to achieving hemostasis for the subject. The "hemostasis" here refers to that at the puncture site, there is no pulsating bleeding, nor expansionary/progressive hematoma.

Time frame:
Post procedure (time from the sheath removal to the time to achieving hemostasis)
Reported as:
Mean · Min
Primary Effectiveness Endpoint: Time to Hemostasis
MinMynxGripManual Compression
Primary Effectiveness Endpoint: Time to Hemostasis4.8 ± 12.1019.8 ± 25.37
PrimaryPrimary Safety Endpoint: Major Complication Rate

Defined as major complications during procedure, at discharge, and 30 days post procedure: vascular injury or vascular repair required; Permanent access site-related nerve injury; Access site-related nerve injury requiring a surgery; Access site-related bleeding requiring transfusion; New ipsilateral lower extremity ischemia discovered, which requires invasive/noninvasive intervention; Local access site-related infection combined with other indicators, which requires intervention; Classic signs/symptoms occurred in a short time after receiving the specified hemostasis procedures and generalized infection with positive blood culture, sepsis, which requiring intervention; Inflammatory reaction, including the local reaction and discharge of pus, which requires intervention

Time frame:
Through 30 days post procedure
Reported as:
Number · percentage of participants
Primary Safety Endpoint: Major Complication Rate
percentage of participantsMynxGripManual Compression
Primary Safety Endpoint: Major Complication Rate00
SecondarySecondary Effectiveness Endpoint: Time to Ambulation

Defined as the time (in minutes) from sheath removal to when the patient can walk about at least 6 meters (or 20 steps). Compare whether there are differences in the time to ambulation (for patients receiving a diagnostic procedure) between the two groups.

Time frame:
Post procedure
Reported as:
Mean · Min
Secondary Effectiveness Endpoint: Time to Ambulation
MinMynxGripManual Compression
Secondary Effectiveness Endpoint: Time to Ambulation657.0 ± 641.641306.3 ± 269.84
SecondarySecondary Effectiveness Endpoint: Length of Hospital Stay

Defined as the time (in minutes) from sheath removal to patient discharge (for patients receiving a diagnostic procedure). Compare whether there are differences in the length of stay (for patients receiving a diagnostic procedure) between the two groups.

Time frame:
Index procedure through discharge
Reported as:
Mean · Min
Secondary Effectiveness Endpoint: Length of Hospital Stay
MinMynxGripManual Compression
Secondary Effectiveness Endpoint: Length of Hospital Stay3104.9 ± 2356.682721.1 ± 1676.36
SecondarySecondary Effectiveness Endpoint: Procedure Success Rate

Defined as successfully achieving hemostasis using the investigational medical device or control methods (including but are not limited to the assigned therapeutic method and other supplementary means) with absence of major complications. Compare whether there are differences in the procedure success rate (for patients receiving a diagnostic procedure) between the two groups.

Time frame:
Index procedure
Reported as:
Count of participants · Participants
Secondary Effectiveness Endpoint: Procedure Success Rate
ParticipantsMynxGripManual Compression
Secondary Effectiveness Endpoint: Procedure Success Rate202101
SecondarySecondary Effectiveness Endpoint: Device Success Rate

Defined as the device being successfully removed in accordance with the standard operating procedure

Time frame:
Intraoperatively
Reported as:
Count of participants · Participants
Secondary Effectiveness Endpoint: Device Success Rate
ParticipantsMynxGrip
Secondary Effectiveness Endpoint: Device Success Rate194
SecondarySecondary Safety Endpoint: Minor Complication Rate

Compare whether there are differences in rates of minor complications between the two groups

Time frame:
Through 30 days post procedure
Reported as:
Number · percentage of participants
Secondary Safety Endpoint: Minor Complication Rate
percentage of participantsMynxGripManual Compression
Secondary Safety Endpoint: Minor Complication Rate31

Adverse events

Collected over 30 days follow-up. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MynxGrip0/204 (0%)10/204 (4.9%)65/204 (31.9%)
Manual Compression0/101 (0%)2/101 (2%)20/101 (19.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventMynxGripManual Compression
Left Intracranial HemorrhageNervous system disorders0/2041/101
CholecystitisHepatobiliary disorders0/2041/101
Retroperitoneal HematomaGastrointestinal disorders1/2040/101
Heart DiseaseCardiac disorders1/2040/101
Lung CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2040/101
Splenic InfarctionBlood and lymphatic system disorders1/2040/101
AneurysmNervous system disorders1/2040/101
Moyamoya DiseaseNervous system disorders1/2040/101
Nasopharyngeal FibroangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2040/101
Renal Artery Dissection AneurysmRenal and urinary disorders1/2040/101
Most frequent other events
Showing 10 of 45
Most frequent other events
EventMynxGripManual Compression
Induration at the puncture siteGeneral disorders9/2040/101
VomitGastrointestinal disorders5/2043/101
Swelling at puncture siteGeneral disorders5/2040/101
NauseaGastrointestinal disorders5/2041/101
Hematoma at vascular puncture siteGeneral disorders3/2042/101
FeverGeneral disorders1/2042/101
Stomach AcheGastrointestinal disorders3/2042/101
Upper Abdominal PainGastrointestinal disorders0/2042/101
Presence of HematuriaRenal and urinary disorders4/2041/101
Increased Blood PressureGeneral disorders3/2041/101

Baseline characteristics

One subject in the test group and one in the control group were excluded from the full analysis set (FAS) and the per-protocol population set (PPS). One subject in the test group was re-enrolled because it met the exclusion criteria 21, and one in the control group withdrew informed consent before receiving the trial treatment after randomization. In the end, the FAS included 304 subjects, including 203 subjects in the test group and 101 subjects in the control group.

Age, Continuous
Age, Continuous(Years)MynxGripManual CompressionTotal
Mean59.8 ± 10.8359.7 ± 10.6059.8 ± 10.74
Sex: Female, Male
Sex: Female, Male(Participants)MynxGripManual CompressionTotal
Female13069199
Male7332105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MynxGripManual CompressionTotal
Han19197288
Other12416
Height
Height(m)MynxGripManual CompressionTotal
Mean1.661 ± 0.08031.661 ± 0.07411.661 ± 0.0781
Weight
Weight(Kg)MynxGripManual CompressionTotal
Mean69.09 ± 10.66970.14 ± 10.38369.44 ± 10.569
BMI
BMI(Kg/m^2)MynxGripManual CompressionTotal
Mean24.98 ± 2.95025.38 ± 3.09225.12 ± 2.998
08

Study locations

1 site
  • Beijing Tiantan Hospital Capitol Medical University
    Beijing, 100068, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Oct 2020, 17 months.

Results were first posted in Jul 2026, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 22, 2019
StartActual
Apr 24, 2019
Primary completionActual
Oct 22, 2020
CompletionActual
Oct 22, 2020
Results first posted
Jul 29, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03923387
Lead sponsor
Cordis US Corp.
Collaborators
Kun Tuo
Responsible party
Sponsor
First posted
Apr 22, 2019
Start date
Apr 24, 2019
Primary completion
Oct 22, 2020
Completion
Oct 22, 2020
Results posted
Jul 29, 2026
Last update
Jul 29, 2026

Study contacts

Prof. Miao Zhongrong, MD
principal investigator · Beijing Tian Tan Hospital, Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion